14
Views
120
CrossRef citations to date
0
Altmetric
Original Article

Transitional Cell Tumors of the Renal Pelvis in Analgesic Abusers

, , &
Pages 145-150 | Received 01 Feb 1968, Published online: 09 Jul 2009
 

Abstract

In a clinical series of 242 patients with chronic non-obstructive pyelonephritis, 142 patients were classed as chronic abusers of drugs containing phenacetin. Seventy-nine per cent of all the patients were followed up for one to eleven years (average 5.3 years). Eight patients (about 8 per cent) in the group of analgesic abusers developed transitional cell tumors of the renal pelvis, but no such tumors arose in the non-abusers.

In the adjacent surgical department transitional cell tumor was diagnosed in another five analgesic abusers during the past eight years. The group of analgesic abusers with renal pelvic tumor (13 patients) was compared with a group of non-abusers with such tumors (15 patients) from the same surgical department. The mean age of the patients in the first group was lower and females were in the majority, while in the second group elderly men with prostatic hyperplasia predominated.

Tumor differentiation tended to be lower and infiltrative growth more frequent in the analgesic abusers. This may have been due to the later diagnosis in this group. Suggestive circumstantial evidence of a carcinogenic effect by phenacetin-containing drugs is discussed.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.